Applied genetics

Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Retrieved on: 
Tuesday, August 3, 2021

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.
  • Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality.
  • Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP.
  • In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences

Retrieved on: 
Monday, August 2, 2021

Webcasts for these conferences will be available in the Events & Media section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations .

Key Points: 
  • Webcasts for these conferences will be available in the Events & Media section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations .
  • Archived versions of the webcasts will be available on the website for 60 days.
  • Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease.
  • We have combined our teams proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.

Global Neoantigen Cancer Vaccine Markets, Competition, Forecast & Opportunities, 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021

The "Global Neoantigen Cancer Vaccine Market, By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Neoantigen Cancer Vaccine Market, By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Neoantigen Cancer Vaccine Market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD 1754.44 million by 2026.
  • The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector.
  • The Global Neoantigen Cancer Vaccine Market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company.

Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021

The "Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report by Therapy Type, by Scale (R&D, Commercial), by Mode, by Workflow (Vector Production, Cell Banking), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report by Therapy Type, by Scale (R&D, Commercial), by Mode, by Workflow (Vector Production, Cell Banking), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global cell and gene therapy manufacturing market size is expected to reach USD 57.4 billion by 2028.
  • An exponential rise in clinical pipeline coupled with a rising number of regulatory approvals for advanced therapies has majorly driven the market.
  • Several novel methods are being introduced to advance cell and gene therapy manufacturing.

SalioGen Therapeutics Strengthens Management with Key Additions to Leadership Team to Advance Its Gene Coding Platform

Retrieved on: 
Wednesday, July 28, 2021

CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- SalioGen Therapeutics, a privately held biotechnology company developing durable and broadly applicable genetic medicines through Gene Coding, today announced that the Company has strengthened its management team with multiple leadership appointments of renowned experts in their respective fields. Sung You, M.S., MBA, will join as Chief Business and Strategy Officer, Nancy L. Craig, Ph.D., will join as Senior Vice President of Genetic Engineering, and Sandeep Nema, Ph.D., will join as Senior Vice President of Technical Operations.

Key Points: 
  • Sandeep has a wealth of background in shepherding novel therapeutics in a broad spectrum of modalities through scale-up and clinical trials.
  • Together and alongside our current management team, they will be instrumental at this critical period as we prepare in vivo proof-of-concept studies and IND-enabling studies to explore the potential of SalioGens Gene Coding approach.
  • Dr. Craig is widely regarded as a pioneer in the study of mobile genetic elements, the basis for SalioGens Gene Coding technology.
  • SalioGen Therapeutics is advancing Gene Coding to develop durable, broadly applicable genetic medicines, initially using its Exact DNA Integration Technology (EDIT) platform.

Apic Bio Receives FDA Fast Track Designation for APB-102 for the Treatment of Patients with SOD1 ALS

Retrieved on: 
Wednesday, July 28, 2021

Drugs that receive a Fast Track designation are eligible for more frequent meetings and written communication with the FDA to discuss development plans and clinical trial design.

Key Points: 
  • Drugs that receive a Fast Track designation are eligible for more frequent meetings and written communication with the FDA to discuss development plans and clinical trial design.
  • APB-102 is a gene therapy candidate being evaluated for the potential treatment of SOD1 ALS.
  • Apic Bio is an innovative gene therapy company focused on developing first-in-class treatment options for rare, undertreated neurological and liver diseases.
  • The Companys lead program is an adeno-associated (AAV)-based gene therapy for the treatment of SOD1 ALS.

Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Acidemia

Retrieved on: 
Monday, July 26, 2021

WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of world renowned AAV gene therapy pioneer Jude Samulski, Ph.D., as a special advisor to assist with the development of their gene therapy programs. Additionally, Selecta has published a peer-reviewed online article describing pre-clinical data from its study investigating the efficacy of co-administration of ImmTOR™ nanoparticles with AAV vectors in transgene expression in methylmalonic acidemia (MMA) in the journal Molecular Therapy Methods & Clinical Development. The publication, entitled, “ImmTOR nanoparticles enhance AAV-driven transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia,” was led by Petr Ilyinskii, Ph.D., a senior director at Selecta.

Key Points: 
  • Overcoming immunogenicity is a huge challenge for the entire gene therapy field, said Dr. Samulski.
  • The preclinical data presented in this study supports Selectas ImmTOR technology potential to be a game-changing technology.
  • Dr. Samulski is professor of pharmacology and has been the director of the University of North Carolina Gene Therapy Center for over two decades.
  • Repeated administration of AAV vectors enabled by ImmTOR resulted in increased vector transduction and further decreases in plasma methylmalonic acid that was dose dependent.

Spark Therapeutics’ SPK-8011 Suggests Stable and Durable Factor VIII Expression in Largest Phase 1/2 Gene Therapy Study in Hemophilia A to Date

Retrieved on: 
Wednesday, July 21, 2021

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated data from the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A during the International Society of Thrombosis and Hemostasis (ISTH) 2021 Virtual Congress (July 17-21). The data will be shared as an oral presentation today, July 21 at 10:12 a.m. EST. (Abstract OC 67.2)

Key Points: 
  • We remain focused on optimizing the dose and immunomodulatory regimen in the phase 1/2 study and look forward to continuing our evaluation of this therapy in a Phase 3 study.
  • Eighteen participants in the Phase 1/2 trial received a single administration of investigational SPK-8011 in four dose cohorts, ranging from 5x1011 vg/kg to 21012 vg/kg.
  • These data reinforce the ability of AAV gene therapy targeting hepatocytes to achieve stable and durable FVIII expression with an acceptable safety profile.
  • Pairing Roches long-standing commitment to developing medicines in hemophilia with Spark Therapeutics proven gene therapy expertise brings together the best team of collaborators researching gene therapies in hemophilia A.

GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership

Retrieved on: 
Thursday, July 15, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210715005550/en/
    Forge will provide adeno-associated viral (AAV) vector process and analytical development, scale-up engineering and GMP manufacturing services for GentiBios engineered Tregs therapeutic candidates.
  • All development and GMP activities will occur at The Hearth, Forges 175,000 ft2 gene therapy GMP production facility in Columbus, Ohio.
  • Forge offers a broad array of services ranging from process development to GMP manufacturing, making them a strong partner for GentiBios cell therapies with capacity to support GentiBio as we advance programs through clinical development.
  • To learn more, visit https://www.gentibio.com
    Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company.

GenScript to Host Gene & Cell Engineering Virtual Summit

Retrieved on: 
Tuesday, July 13, 2021

PISCATAWAY, N.J., July 13, 2021 /PRNewswire/ -- GenScript , the world's leading life science service provider, announced today the first GenScript Gene & Cell Engineering Virtual Summit, featuring in-depth discussions and research presentations on the gene synthesis and cell editing technologies that are transforming scientific and biomedical research today.

Key Points: 
  • PISCATAWAY, N.J., July 13, 2021 /PRNewswire/ -- GenScript , the world's leading life science service provider, announced today the first GenScript Gene & Cell Engineering Virtual Summit, featuring in-depth discussions and research presentations on the gene synthesis and cell editing technologies that are transforming scientific and biomedical research today.
  • The free Summit will be held on July 22 from 11 a.m. to 6 p.m., with specialized tracks on Expanding the CRISPR Toolbox, Genome Editing in Cell & Gene Therapy, and Enzyme and AAV Engineering.
  • The presentation will highlight discoveries in elucidating T cell- and tumor-cell-intrinsic determinants of CAR T cell efficacy, and will be followed by a question-and-answer session.
  • "As a leader in gene synthesis and gene editing technologies, GenScript has been fortunate to work with many of the pioneering scientists in cell and gene engineering," added Chen.